◎ Sugi Atlas

Atlas / Disease / Urticaria

Urticaria

disease
On this page

Also known as hivesurticaria (disease)Urticarias

Summary

Urticaria (MONDO:0005492) is a disease (an umbrella term covering 14 Mondo subtypes) with 8 cohort genes (52 GWAS associations across 25 studies) and 83 clinical trials. Top therapeutic interventions include desloratadine, cetirizine, and fexofenadine.

At a glance

  • Umbrella term: 14 Mondo subtypes
  • Cohort genes: 8
  • GWAS associations: 52
  • ClinVar variants: 2
  • Clinical trials: 83

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

FieldValue
Canonical nameurticaria
Mondo IDMONDO:0005492
EFOEFO:0005531
MeSHD014581
DOIDDOID:1555
ICD-10-CML50
NCITC3432
SNOMED CT126485001
UMLSC0042109
MedGen22587
Is cancer (heuristic)no

Also known as: hives · urticaria · urticaria (disease) · Urticarias

Data availability: 2 ClinVar variants · 52 GWAS associations (25 studies) · 1 HPO phenotype.

Disease family

An umbrella term covering 14 Mondo subtypes.

Classification path: disease › human disease › disease by body system or component › integumentary system disorder › skin disorder › dermatitis › urticaria

Related subtypes (32): spongiotic dermatitis, atopic eczema, psoriasis, contact dermatitis, acneiform dermatitis, acrodermatitis, folliculitis, granuloma annulare, granulomatous dermatitis, lichen planus, neurodermatitis, neurotic excoriation, parapsoriasis, pityriasis rosea, seborrheic dermatitis, acanthosis nigricans, dermatosis papulosa nigra, lichen sclerosus et atrophicus, vitiligo, acne, porphyria cutanea tarda, dermatomyositis, acute generalized exanthematous pustulosis, hydroa vacciniforme, autoimmune bullous skin disease, cutaneous vasculitis, skin infection, intertrigo, lipodermatosclerosis, exfoliative dermatitis, radiodermatitis, food dermatitis

Subtypes (14): allergic urticaria, physical urticaria, Melkersson-Rosenthal syndrome, pruritic urticarial papules and plaques of pregnancy, urticaria, aquagenic, urticaria, familial localized heat, angioedema, drug rash with eosinophilia and systemic symptoms, cutaneous mastocytosis, cold urticaria, autoimmune urticaria, papular urticaria, idiopathic urticaria, chronic urticaria

Genetics & variants

GWAS landscape

52 GWAS associations across 25 studies. Top hits map to 26 distinct genes (as reported by GWAS).

Top associations by p-value

rsIDp-valueGeneRisk alleleOdds ratio
rs560430704e-44GCSAMLA1.24
rs742277093e-21GCSAMLA1.25
rs1177544602e-19ZNF728C3.49
rs67033488e-18OR10J3 - OR10J7PG0.92
rs4341242e-15MIR4752 - LILRA5C1.9
chr1:2475592863e-15A0.2
rs3864806e-15WHR1G0.93
rs1438715152e-14CTAAT0.93
rs358340084e-14CBLBC1.11
rs1392999447e-14HLA-DQA1C1.1
rs341413825e-13HLA-DQA1C1.74
rs564048005e-13ZNF469 - ZFPM1A0.94
rs124930053e-12TBL1XR1T1.06
rs44100777e-12TPSAB1 - TPSD1T1.07
rs5486636942e-11CNTRLT1.89
rs619861822e-10IGHA1C1.51
rs730755713e-10LRRC2 - FAM240AG1.63
rs1180706753e-10CACNA1HC1.18
rs30249711e-09STAT6G0.91
rs110306393e-09STIM1G0.1
chr4:1234968934e-09C2.95
rs93781416e-09POLR1HASP, POLR1HASPC1.41
rs37509969e-09STIM1G0.12
rs1435477881e-08TPSB2C0.14
rs37896122e-08PTPN22, AP4B1-AS1T2.01
rs10972962e-08ITPKB - RPS27P5C1.44
chr10:1156212992e-08A1.33
chr3:1478593682e-08GT0.27
rs22745693e-08SLC35A3C11.78
rs731415334e-08LINC02421 - LINC01479C1.41

Top studies (by case count)

StudyLead authorYearCasesControlsTitle
GCST90565360McSweeney SM202314,306650,664Genome-wide meta-analysis implicates variation affecting mast cell biology in urticaria.
GCST90473943UK Biobank Whole-Genome Sequencing Consortium202510,191448,249Whole-genome sequencing of 490,640 UK Biobank participants.
GCST90667818UK Biobank Whole-Genome Sequencing Consortium202510,191448,249Whole-genome sequencing of 490,640 UK Biobank participants.
GCST90310300Kristjansson RP20239,893162,190Sequence variant affects GCSAML splicing, mast cell specific proteins, and risk of urticaria.
GCST90018716Sakaue S20219,893162,190A cross-population atlas of genetic associations for 220 human phenotypes.
GCST90651224Liu TY20255,699199,253Diversity and longitudinal records: Genetic architecture of disease associations and polygenic risk in the Taiwanese Han population.
GCST90476291Verma A20245,310435,807Diversity and scale: Genetic architecture of 2068 traits in the VA Million Veteran Program.
GCST90727291Kim HI20263,28040,746Exome sequencing and analysis of 44,028 British South Asians enriched for high autozygosity.
GCST90727038Kim HI20263,25940,767Exome sequencing and analysis of 44,028 British South Asians enriched for high autozygosity.
GCST90479309Verma A20242,350115,783Diversity and scale: Genetic architecture of 2068 traits in the VA Million Veteran Program.

Variant details and genetic-evidence tiers

Tier distribution (top 50 variants)

TierVariants
Tier 1: coding0
Tier 2: splice/UTR3
Tier 3: regulatory1
Tier 4: intronic/intergenic40

MAF distribution

BucketVariants
common (>=0.05)32
low_freq (0.01-0.05)3
rare (<0.01)1
unknown8

Functional consequences

ConsequenceCount
intron_variant23
unknown9
intergenic_variant7
splice_donor_variant1
regulatory_region_variant1
3_prime_UTR_variant1
5_prime_UTR_variant1
non_coding_transcript_exon_variant1

Top variants

rsIDChrPosAllelesMAFConsequenceGenep-valueTier
rs560430701247556467G>A,T0.066splice_donor_variantGCSAML4e-44Tier 2: splice/UTR
rs742277091247559286G>A0.065intron_variantGCSAML3e-21Tier 4: intronic/intergenic
rs1177544601922989871T>C0.02intron_variantZNF7282e-19Tier 4: intronic/intergenic
rs67033481159321893C>A,G,T0.288intergenic_variantOR10J3 - OR10J7P8e-18Tier 4: intronic/intergenic
rs4341241954298727G>C0.11intron_variantMIR4752 - LILRA52e-15Tier 4: intronic/intergenic
chr1:2475592863e-15Tier 4: intronic/intergenic
rs386480631979060C>G,T0.349intron_variantWHR16e-15Tier 4: intronic/intergenic
rs1438715150.3262e-14Tier 4: intronic/intergenic
rs358340083105668386C>A,T0.308intron_variantCBLB4e-14Tier 4: intronic/intergenic
rs139299944632634889C>CT0.406intergenic_variantHLA-DQA17e-14Tier 4: intronic/intergenic
rs34141382632640701T>C,G0.05intron_variantHLA-DQA15e-13Tier 4: intronic/intergenic
rs564048001688449304T>A,C,G0.283regulatory_region_variantZNF469 - ZFPM15e-13Tier 3: regulatory
rs124930053177195111C>T0.41intron_variantTBL1XR13e-12Tier 4: intronic/intergenic
rs4410077161253082C>T0.461intergenic_variantTPSAB1 - TPSD17e-12Tier 4: intronic/intergenic
rs5486636949121141725T>C0intron_variantCNTRL2e-11Tier 4: intronic/intergenic
rs6198618214105704334T>C0.22intron_variantIGHA12e-10Tier 4: intronic/intergenic
rs73075571346608221A>G0.13intron_variantLRRC2 - FAM240A3e-10Tier 4: intronic/intergenic
rs118070675161206902C>G0.061intron_variantCACNA1H3e-10Tier 4: intronic/intergenic
rs30249711257099944T>G0.102intron_variantSTAT61e-09Tier 4: intronic/intergenic
rs11030639114017826A>G,T0.305intron_variantSTIM13e-09Tier 4: intronic/intergenic
chr4:1234968934e-09Tier 4: intronic/intergenic
rs9378141629970591A>C0.31intron_variantPOLR1HASP, POLR1HASP6e-09Tier 4: intronic/intergenic
rs3750996114091970A>G0.053_prime_UTR_variantSTIM19e-09Tier 2: splice/UTR
rs143547788161230086G>A,C,T0.055_prime_UTR_variantTPSB21e-08Tier 2: splice/UTR
rs37896121113871486C>A,T0.04intron_variantPTPN22, AP4B1-AS12e-08Tier 4: intronic/intergenic
rs10972961226755787C>G,T0.05intergenic_variantITPKB - RPS27P52e-08Tier 4: intronic/intergenic
chr10:1156212992e-08Tier 4: intronic/intergenic
chr3:1478593682e-08Tier 4: intronic/intergenic
rs2274569199969523T>C,G0.066non_coding_transcript_exon_variantSLC35A33e-08Tier 4: intronic/intergenic
rs731415331267790627C>A,T0.012intergenic_variantLINC02421 - LINC014794e-08Tier 4: intronic/intergenic

ClinVar germline variants

2 retrieved; paginated sample, class counts are floors:

1 pathogenic, 1 conflicting classifications of pathogenicity

ClinVarVariant (HGVS)GeneClassificationReview
1170NM_000505.4(F12):c.983C>G (p.Thr328Arg)F12Pathogeniccriteria provided, single submitter
2547NM_000243.3(MEFV):c.2084A>G (p.Lys695Arg)LOC126862264Conflicting classifications of pathogenicitycriteria provided, conflicting classifications

Genes & proteins

Mendelian disease overlap and somatic drivers

GenCC: 0 · Orphanet: 9 · OMIM-shared: 0 · Dual-evidence (GWAS+Mendelian): 0

Orphanet rare-disease linkage (cohort genes)

GeneOrphanet IDRare disease
RIMS1Orphanet:1872Cone rod dystrophy
IFT43Orphanet:1515Cranioectodermal dysplasia
IFT43Orphanet:791Retinitis pigmentosa
F12Orphanet:100054F12-related hereditary angioedema with normal C1Inh
F12Orphanet:330Congenital factor XII deficiency
F12Orphanet:617919F12-associated cold autoinflammatory syndrome
AKAP9Orphanet:101016Romano-Ward syndrome
AKAP9Orphanet:130Brugada syndrome
HLFOrphanet:641375B-lymphoblastic leukemia/lymphoma with t(17;19)

Cohort genes → proteins

8 cohort genes, 8 distinct canonical proteins.

Evidence partition

SubsetGenes
gwas_only7
multi_evidence1

Cohort genes (full)

SymbolHGNCEnsemblUniProtNameEvidence
ABI3BPHGNC:17265ENSG00000154175Q7Z7G0Target of Nesh-SH3gwas
RIMS1HGNC:17282ENSG00000079841Q86UR5Regulating synaptic membrane exocytosis protein 1gwas
RGMBHGNC:26896ENSG00000174136Q6NW40Repulsive guidance molecule Bgwas
IFT43HGNC:29669ENSG00000119650Q96FT9Intraflagellar transport protein 43 homologgwas
F12HGNC:3530ENSG00000131187P00748Coagulation factor XIIclinvar
AKAP9HGNC:379ENSG00000127914Q99996A-kinase anchor protein 9gwas
HLFHGNC:4977ENSG00000108924Q16534Hepatic leukemia factorgwas
RAD51BHGNC:9822ENSG00000182185O15315DNA repair protein RAD51 homolog 2gwas

Cohort function summary

Lead sentence per gene, UniProt-curated.

SymbolProtein nameFunction (lead sentence)
RIMS1Regulating synaptic membrane exocytosis protein 1Rab effector involved in exocytosis.
RGMBRepulsive guidance molecule BMember of the repulsive guidance molecule (RGM) family that contributes to the patterning of the developing nervous system.
IFT43Intraflagellar transport protein 43 homologAs a component of IFT complex A (IFT-A), a complex required for retrograde ciliary transport and entry into cilia of G protein-coupled receptors (GPCRs), it is involved in ciliogenesis.
F12Coagulation factor XIIFactor XII is a serum glycoprotein that participates in the initiation of blood coagulation, fibrinolysis, and the generation of bradykinin and angiotensin.
AKAP9A-kinase anchor protein 9Scaffolding protein that assembles several protein kinases and phosphatases on the centrosome and Golgi apparatus.
RAD51BDNA repair protein RAD51 homolog 2Involved in the homologous recombination repair (HRR) pathway of double-stranded DNA breaks arising during DNA replication or induced by DNA-damaging agents.

Protein-family classification

Druggable: 2 · Difficult: 1 · Unknown: 5 · Druggable fraction: 0.25

Family distribution

Cohort families vs a genome-wide background (hypergeometric, BH-FDR; fold = observed/expected). Counts kept; sorted by enrichment, so the catch-all Other/Unknown bucket no longer leads.

FamilyGenesFoldFDR
Protease14.6×0.487
Antibody/Immunoglobulin13.6×0.487
Other/Unknown51.1×0.644
Transcription factor11.0×0.644

Per-gene assignment

SymbolFamilyDruggable?ECInterPro (top 3)
ABI3BPAntibody/ImmunoglobulinyesFN3_dom, Ig-like_fold, FN3_sf
RIMS1Transcription factornoC2_dom, PDZ, Rab_BD
RGMBOther/UnknownnoRGM_C, RGM_N, RGM
IFT43Other/UnknownnoIFT43
F12Proteaseyes3.4.21.38Kringle, Fibronectin_type1, FN_type2_dom
AKAP9Other/UnknownnoELK_dom, PACT_domain, AKAP9/Pericentrin
HLFOther/UnknownnobZIP, PAR_bZIP, bZIP_sf
RAD51BOther/UnknownnoAAA+_ATPase, Rad51_C, DNA_recomb/repair_RecA-like

Expression context

Cohort genes with no expression data: 0.

8 cohort genes are a single-cell marker in ≥1 SCXA experiment.

Breadth distribution (Bgee present_calls)

BucketGenes
narrow (1-5 tissues)0
moderate (6-20)0
broad (>20)8
unknown0

Top tissues across cohort

TissueCohort genes
calcaneal tendon2
bronchial epithelial cell2
decidua1
synovial joint1
cerebellar cortex1
cerebellar hemisphere1
cerebellum1
ileal mucosa1
pylorus1
upper arm skin1
bronchus1
right uterine tube1
gingival epithelium1
liver1
right lobe of liver1
cortical plate1
jejunal mucosa1
Brodmann (1909) area 461
orbitofrontal cortex1
buccal mucosa cell1

Per-gene tissue summary (top 30)

SymbolBgee breadthFANTOM5 breadthSCXATop tissues
ABI3BP256ubiquitousmarkerdecidua, synovial joint, calcaneal tendon
RIMS1175broadmarkercerebellar cortex, cerebellar hemisphere, cerebellum
RGMB254ubiquitousmarkerileal mucosa, pylorus, upper arm skin
IFT43252ubiquitousmarkerright uterine tube, bronchial epithelial cell, bronchus
F12191broadmarkerright lobe of liver, liver, gingival epithelium
AKAP9292ubiquitousmarkerjejunal mucosa, bronchial epithelial cell, cortical plate
HLF275broadmarkercalcaneal tendon, orbitofrontal cortex, Brodmann (1909) area 46
RAD51B193ubiquitousmarkersural nerve, buccal mucosa cell, male germ line stem cell (sensu Vertebrata) in testis

Protein interactions among cohort

Intra-cohort edges: 0.

Hub genes (top 10 by interactor count)

SymbolInteractor count
F123,850
AKAP93,537
RAD51B2,993
RIMS11,987
HLF903
ABI3BP767
IFT43635
RGMB531

Structural data

PDB: 5 · AlphaFold-only: 3 · No structure: 0

Cohort genes with PDB structures (top 30)

SymbolUniProtPDB entries
F12P0074817
RGMBQ6NW4011
RAD51BO153155
IFT43Q96FT93
RIMS1Q86UR51

AlphaFold-only cohort genes (top 30 by pLDDT)

SymbolUniProtpLDDT
HLFQ1653472.55
ABI3BPQ7Z7G054.33
AKAP9Q99996

Function

Pathway analysis

Distinct Reactome pathways touched by cohort: 48. Enrichment computed across 8 evidence-associated genes (6 with Reactome annotation).

Pathways by enrichment

Over-representation of cohort genes vs the genome-wide background (hypergeometric test, Benjamini-Hochberg FDR; fold = observed/expected over 6 annotated cohort genes). Counts and members are kept as ground-truth; sorted by enrichment.

PathwayCohort genesFoldFDRSample cohort genes
Aggregated β-amyloid induces FXII autocatalysis1951.7×0.034F12
Defective factor XII causes hereditary angioedema1475.8×0.034F12
Defective SERPING1 causes hereditary angioedema1475.8×0.034F12
Phase 3 - rapid repolarisation1190.3×0.038AKAP9
Regulation of FXIIa and plasma kallikrein activity1190.3×0.038F12
FXIIa, PKa-dependent activation of coagulation pathway1190.3×0.038F12
Phase 2 - plateau phase1126.9×0.038AKAP9
Acetylcholine Neurotransmitter Release Cycle1112.0×0.038RIMS1
Serotonin Neurotransmitter Release Cycle1105.7×0.038RIMS1
Norepinephrine Neurotransmitter Release Cycle1105.7×0.038RIMS1
GABA synthesis, release, reuptake and degradation1105.7×0.038RIMS1
Dopamine Neurotransmitter Release Cycle182.8×0.038RIMS1
Glutamate Neurotransmitter Release Cycle176.1×0.038RIMS1
Impaired BRCA2 binding to PALB2176.1×0.038RAD51B
Netrin-1 signaling173.2×0.038RGMB
Defective homologous recombination repair (HRR) due to BRCA1 loss of function170.5×0.038RAD51B
Defective HDR through Homologous Recombination Repair (HRR) due to PALB2 loss of BRCA1 binding function170.5×0.038RAD51B
Defective HDR through Homologous Recombination Repair (HRR) due to PALB2 loss of BRCA2/RAD51/RAD51C binding function170.5×0.038RAD51B
Resolution of D-loop Structures through Synthesis-Dependent Strand Annealing (SDSA)165.6×0.038RAD51B
Homologous DNA Pairing and Strand Exchange163.4×0.038RAD51B
Resolution of D-loop Structures through Holliday Junction Intermediates150.1×0.045RAD51B
Presynaptic phase of homologous DNA pairing and strand exchange145.3×0.048RAD51B
Centrosome maturation142.3×0.048AKAP9
Oncogenic MAPK signaling141.4×0.048AKAP9
Intraflagellar transport133.4×0.057IFT43
HDR through Homologous Recombination (HRR)131.7×0.057RAD51B
FXIIa activates plasma kallikrein-kinin system128.8×0.059F12
Signaling by BRAF and RAF1 fusions128.4×0.059AKAP9
Loss of Nlp from mitotic centrosomes126.4×0.060AKAP9
Loss of proteins required for interphase microtubule organization from the centrosome126.4×0.060AKAP9

GO biological processes by enrichment

Over-representation of cohort genes vs the genome-wide background (hypergeometric test, Benjamini-Hochberg FDR; fold = observed/expected over 8 annotated cohort genes). Counts and members are kept as ground-truth; sorted by enrichment.

GO termCohort genesFoldFDRSample cohort genes
plasma kallikrein-kinin cascade11053.2×0.022F12
Factor XII activation1702.2×0.022F12
response to misfolded protein1702.2×0.022F12
positive regulation of fibrinolysis1421.3×0.022F12
blastocyst growth1351.1×0.022RAD51B
maintenance of centrosome location1351.1×0.022AKAP9
acrosomal vesicle exocytosis1351.1×0.022RIMS1
positive regulation of inhibitory postsynaptic potential1351.1×0.022RIMS1
blood coagulation, intrinsic pathway1263.3×0.022F12
secretion1263.3×0.022RIMS1
positive regulation of plasminogen activation1234.1×0.022F12
regulation of cardiac muscle cell action potential involved in regulation of contraction1234.1×0.022AKAP9
obsolete synaptic vesicle docking1162.0×0.024RIMS1
regulation of membrane repolarization1162.0×0.024AKAP9
positive regulation of blood coagulation1140.4×0.024F12
intraciliary retrograde transport1140.4×0.024IFT43
somite development1140.4×0.024RAD51B
regulation of Golgi organization1140.4×0.024AKAP9
calcium-ion regulated exocytosis1123.9×0.024RIMS1
protein-containing complex localization1123.9×0.024AKAP9
regulated exocytosis1110.9×0.024RIMS1
fibrinolysis1105.3×0.024F12
regulation of ventricular cardiac muscle cell membrane repolarization1105.3×0.024AKAP9
synaptic vesicle priming1100.3×0.024RIMS1
synaptic vesicle exocytosis195.8×0.024RIMS1
regulation of neurotransmitter secretion195.8×0.024RIMS1
positive regulation of dendrite extension191.6×0.024RIMS1
positive regulation of microtubule polymerization184.3×0.024AKAP9
zymogen activation184.3×0.024F12
protein autoprocessing181.0×0.024F12

Therapeutics

Drugs indicated for this disease

4 approved, 7 in late-stage (phase 3) trials. Disease-direct ChEMBL indications, not inferred from the associated-gene cohort below.

DrugDevelopment status
DesloratadineApproved (phase 4)
EpinephrineApproved (phase 4)
LoratadineApproved (phase 4)
OmalizumabApproved (phase 4)
BilastinePhase 3 (in late-stage trials)
CholecalciferolPhase 3 (in late-stage trials)
DiphenhydraminePhase 3 (in late-stage trials)
DoxepinPhase 3 (in late-stage trials)
LevocetirizinePhase 3 (in late-stage trials)
PrednisonePhase 3 (in late-stage trials)
RupatadinePhase 3 (in late-stage trials)

Earlier-phase candidates (phase 2, investigational — efficacy not yet established): Afamelanotide, Cilostazol, Clemastine, Dupilumab, Fenebrutinib, Human Immunoglobulin G, Lirentelimab, Methotrexate, Miltefosine, Titanium Dioxide.

Drug target analysis

Approved (phase 4): 0 · Phase ≥3: 1 · Phased (≥1): 1 · Undrugged: 7

Druggability breadth: 1 of 8 evidence-associated genes (12%) have a ChEMBL target (buckets above are over the deeply-mined display cohort).

Top cohort targets by molecule count

SymbolMoleculesMax phase
F1233
ABI3BP00
RIMS100
RGMB00
IFT4300
AKAP900
HLF00
RAD51B00

Drugs targeting cohort genes (top 30)

MoleculeMax phaseTargets in cohort
NAFAMOSTAT3F12
GABEXATE3F12
SEPIMOSTAT2F12

Bioactivity and enzyme data

Enzyme cohort genes (≥1 EC): 1.

Cohort genes with ChEMBL bioactivity (full, sorted by assay count)

SymbolAssaysType breakdown
F12128Binding:123, Functional:3, ADMET:2

Cohort enzymes (BRENDA EC)

SymbolEC numbersNames
F123.4.21.38coagulation factor XIIa

Cohort genes with high screening signal

≥100 ChEMBL assays — a studied-ness signal; see Therapeutics for approved-drug status.

SymbolChEMBL assays
F12128

Pharmacogenomics

Cohort genes with a PharmGKB record: 8; with CPIC/DPWG dosing guidelines: 0.

No cohort gene has a CPIC/DPWG genotype-guided dosing guideline (PharmGKB).

Chemical tractability of cohort targets

3 approved/phased compounds have measured bioactivity against a cohort gene (and aren’t yet in disease-level trials). This is a research / tractability signal, NOT a therapeutic recommendation — a bioactivity row often reflects off-target or screening binding (e.g. promiscuous kinase inhibitors against a cohort kinase), implying no disease mechanism.

CompoundMax phaseCohort target (bioactivity)
NAFAMOSTAT3F12
GABEXATE3F12
SEPIMOSTAT2F12

Druggability pyramid

Cohort genes binned by druggability tier (high → low):

TierDefinitionGenesSymbols
AApproved (phase 4 drug)0
BPhased (≥1) drug, not yet approved1F12
CDruggable family + PDB, no drug0
DDruggable family + AlphaFold only, no drug1ABI3BP
EDifficult family or no structure, no drug6RIMS1, RGMB, IFT43, AKAP9, HLF, RAD51B

Undrugged target profiles

7 cohort genes are undrugged. Ranked by ‘starting-point quality’ (assay depth + drugged-partner adjacency).

SymbolChEMBL assaysDrugged partners (top 3)
ABI3BP0—
RIMS10—
RGMB0—
IFT430—
AKAP90—
HLF0—
RAD51B0—

Clinical trials & evidence

Clinical trials

Clinical trials: 83.

Phase distribution (across all retrieved trials)

PhaseTrials
Not specified36
PHASE413
PHASE312
PHASE210
PHASE16
PHASE1/PHASE24
PHASE2/PHASE31
EARLY_PHASE11

Top trials by phase / activity

NCTPhaseStatusTitle
NCT00346606PHASE4UNKNOWNThe Efficacy and Safety of Desloratadine With Levocetirizine in Treatment of Chronic Idiopathic Urticaria
NCT00751166PHASE4TERMINATEDA Comparative Double-blind, Double-dummy Study of Desloratadine (DL) 5 mg Once Daily, Cetirizine 10 mg Once Daily, and Placebo Once Daily in Patients With Chronic Idiopathic Urticaria (Study P03736)
NCT00751218PHASE4COMPLETEDA Comparative Double-Blind, Double- Dummy Study of Desloratadine (DL) 5 MG Once Daily, Cetirizine 10 MG Once Daily, and Placebo Once Daily in Patients With Chronic Idiopathic Urticaria (Study P03735)
NCT00783354PHASE4COMPLETEDA Comparison of Aerius Continuous Treatment Versus Aerius PRN for Chronic Idiopathic Urticaria (Study P03147)
NCT00795522PHASE4COMPLETEDAn Open-Label Study of the Effects of Desloratadine (Aerius.) Treatment on the Quality of Life of Patients With Chronic Idiopathic Urticaria (Study P02540)
NCT01444196PHASE4COMPLETEDDesloratadine 5, 10 and 20mg in Patients With Cold Urticaria
NCT01940393PHASE4COMPLETEDEvaluation of the Inhibitory Effect of 5 Anti-Histamines in Urticaria
NCT02392624PHASE4COMPLETEDA Study of the Efficacy and Safety of Omalizumab Through 48 Weeks in Participants With Chronic Idiopathic Urticaria
NCT02550080PHASE4UNKNOWNClinical Utility Of Genetic Screening For HLA-B*1301, On Susceptibility To Dapsone Hypersensitivity Syndrome
NCT02576041PHASE4COMPLETEDEffects of Bilastine on F1 Simulator Driving Performance in Patients Affected by Allergic Rhinitis and/or Urticaria
NCT02742805PHASE4WITHDRAWNSustained Effect of Urticaria Remission With Relatively High Dose Vitamin D Supplementation After Omalizumab Discontinuation
NCT03991845PHASE4UNKNOWNA Trial to Evaluate the Effect of Vitamin D Supplementation in Patients With Chronic Urticaria
NCT04938700PHASE4UNKNOWNStudy on the Correlation Between Intestinal Microecology and Allergic Diseases in Children
NCT06819774PHASE3RECRUITINGPhase III Clinical Study of Cetirizine Hydrochloride Injection in Treatment of Acute Urticaria
NCT00199251PHASE3TERMINATEDEfficacy and Safety of Rupatadine 10 and 20 Mg in Chronic Idiopathic Urticaria
NCT00368823PHASE3COMPLETEDA Trial of Point of Care Information in Ambulatory Pediatrics
NCT00421109PHASE3COMPLETEDEfficacy Study for the Symptomatic Treatment of Chronic Idiopathic Urticaria
NCT00525382PHASE3COMPLETEDStudy to Compare the Efficacy and Safety Between Levocetirizine and Loratadine for Chronic Idiopathic Urticaria
NCT00795158PHASE3COMPLETEDHow Desloratadine (Clarinex, Aerius) Affects Quality of Life in Patients With Chronic Idiopathic Urticaria (Have Had Hives for 6 Weeks or Longer)(Study P02988)
NCT01916967PHASE3COMPLETEDAn Efficacy and Safety Study of Desloratadine (MK-4117) in Japanese Participants With Chronic Urticaria (MK-4117-201)
NCT02023164PHASE3COMPLETEDPilot Phase III Clinical Trial of JDP-205 IV Injection for Treatment of Acute Urticaria
NCT02565680PHASE2/PHASE3COMPLETEDGlucocorticoids With Antihistamines Versus Antihistamines in Acute Urticaria in Emergency
NCT02873364PHASE3UNKNOWNHigh Dose Vitamin D Supplementation in Chronic Spontaneous Urticaria
NCT02935699PHASE3COMPLETEDClinical Trial Comparing JDP-205 to Diphenhydramine Injection for the Treatment of Acute Urticaria
NCT03545464PHASE3COMPLETEDCOrticosteroids in acUte uRticAria in emerGency dEpartment
NCT05115136PHASE3UNKNOWNUsing Doxepin for Urticaria
NCT00069329PHASE1/PHASE2TERMINATEDAnakinra to Treat Patients With Neonatal Onset Multisystem Inflammatory Disease
NCT00129415PHASE1/PHASE2TERMINATEDUltraviolet (UVA and UVB) Light Therapy in the Treatment of Inflammatory Skin Conditions
NCT00130234PHASE2COMPLETEDEffect of Anti-IgE in Chronic Urticaria
NCT00189878PHASE2TERMINATEDA Study of the Use of Methotrexate in the Treatment of Chronic Idiopathic Urticaria
NCT00199238PHASE2TERMINATEDEfficacy of Rupatadine 5, 10 and 20 mg in Chronic Idiopathic Urticaria
NCT00216762PHASE1/PHASE2TERMINATEDSafety Study of Rituximab (Rituxan®) in Chronic Urticaria
NCT00886795PHASE1/PHASE2COMPLETEDSafety and Efficacy of Abatacept in Subjects With Chronic Urticaria Who Have Had an Inadequate Response to Anti-histamine Therapy
NCT01170936PHASE2COMPLETEDIlaris® in Urticarial Vasculitis - Investigation of Treatment Responses
NCT01987947PHASE2COMPLETEDA Study of Quilizumab Versus Placebo in Patients With Refractory Chronic Spontaneous Urticaria
NCT03137069PHASE2COMPLETEDA Study of GDC-0853 in Participants With Refractory Chronic Spontaneous Urticaria (CSU).
NCT03693625PHASE2TERMINATEDA Study to Evaluate the Long-term Safety and Efficacy of Fenebrutinib in Participants Previously Enrolled in a Fenebrutinib Chronic Spontaneous Urticaria (CSU) Study
NCT03968562PHASE2UNKNOWNAssessment of Suppression of Cutaneous Allergic Responses and Pruritus by Topical Doxycycline
NCT05496465PHASE2COMPLETEDSafety and Efficacy of Intranasal Epinephrine After Administration of ARS -1 in Subjects With Frequent Urticaria Flares
NCT05936567PHASE2COMPLETEDStudy Evaluating the Efficacy and Safety of Povorcitinib in Adults With Chronic Spontaneous Urticaria

Drugs tested across these trials (top 30)

MoleculeMax phaseTrials referencing
DESLORATADINE411
CETIRIZINE46
FEXOFENADINE46
BILASTINE44
LEVOCETIRIZINE44
DIPHENHYDRAMINE43
OMALIZUMAB43
RUPATADINE42
ANAKINRA41
CANAKINUMAB41
DAPSONE41
DOXEPIN41
EBASTINE41
ERGOCALCIFEROL41
LORATADINE41
FENEBRUTINIB32
POVORCITINIB31
SYRUP31
CIDOXEPIN21
QUILIZUMAB21
CHEMBL522061801
E-DOXEPIN01

About this page

Generated deterministically by Sugi Atlas from primary biomedical databases via BioBTree. Every record on this page traces to a primary source.

Generated
Atlas version
v1.1.2
BioBTree
v2.0.2

Sources 72

This page pulls from 72 datasets indexed by BioBTree:

alphafoldantibodybgeebgee_evidencebindingdbbiogrid_interactionbrendabrenda_kineticscellosauruschembl_activitychembl_assaychembl_documentchembl_moleculechembl_targetcivic_evidenceclingen_dosageclinical_trialsclinvarctd_gene_interactiondbsnpdepmapdiamond_similaritydoidefoensemblentrezesm2_similarityfantom5_genefantom5_promotergenccgenerifgogtopdbgtopdb_interactiongwasgwas_studyhgncicd10cmintactinterpromedgenmeshmimmondomondochildmondoparentncitorphanetpatentpatent_compoundpdbpfampharmgkb_clinicalpharmgkb_genepharmgkb_guidelinepharmgkb_variantpubchempubchem_activitypubchem_assayreactomerefseqrhearnacentralsctidscxa_expressionscxa_gene_experimentsignorstring_interactiontranscriptufeatureumlsuniprot